PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon Alfa-2b-Njft Investigatng New Dosing Regimen for Patients with Polycythemia Vera (PV)

PharmaEssentia USA Corporation announced that the first patients are now being dosed in ECLIPSE PV, a Phase IIIb clinical study evaluating an accelerated dosing schedule for ropeginterferon alfa-2b-njft using a prefilled syringe for the treatment of adults with PV.